Hamburg Acute Renal Injury (HARIS) cohort
Hamburg Acute Renal Injury Study
This project will follow adults hospitalized with AKI and a group of similar hospitalized patients without AKI to test which clinical factors and blood or urine markers predict recovery and longer-term kidney and cardiovascular problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf Academic / other |
| Locations | 1 site (Hamburg) |
| Trial ID | NCT07338669 on ClinicalTrials.gov |
What this trial studies
HARIS is a prospective observational cohort enrolling adults hospitalized with acute kidney injury and a parallel control group of hospitalized adults with acute illness who did not develop AKI. An IT-supported screening system flags eligible patients in real time, and participants receive standardized clinical assessments, serial lab testing, and repeated blood and urine biosample collection during hospitalization and at three months after discharge. Biospecimens are processed through a harmonized pipeline and stored in the Hamburg and European Renal Omics-Biobank (HERO) to enable biomarker and omics analyses. Annual structured follow-ups capture long-term outcomes including progression to chronic kidney disease, cardiovascular events, hospital readmissions, and mortality.
Who should consider this trial
Good fit: Adults (≥18 years) hospitalized at the University Medical Center Hamburg-Eppendorf who either meet KDIGO criteria for AKI or are hospitalized with acute illness but have not developed AKI, and who can provide informed consent, are ideal candidates.
Not a fit: People who are not hospitalized, are under 18, seek immediate experimental therapy, or require urgent interventional treatment are unlikely to receive direct clinical benefit from this observational protocol.
Why it matters
Potential benefit: If successful, the study could help doctors predict who is at high risk after AKI and guide more personalized follow-up and treatment using validated biomarkers.
How similar studies have performed: Other observational AKI cohorts and biomarker studies have identified promising markers and risk models, but translation into routine clinical practice has been limited and results have been mixed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalized individuals with acute kidney injury (AKI), defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria or hospitalized individuals with acute illness who have not developed AKI (control group) * Age ≥ 18 years at time of enrollment * Personally signed informed consent Exclusion Criteria: * None
Where this trial is running
Hamburg
- Universitätsklinikum Hamburg-Eppendorf — Hamburg, Germany (Recruiting)
Study contacts
- Principal investigator: Tobias B Huber, MD — Universitätsklinikum Hamburg-Eppendorf
- Study coordinator: Christian Schmidt-Lauber, MD
- Email: c.schmidt-lauber@uke.de
- Phone: +49 (0) 40 7410 53908
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.